FibroGen, Inc. (NASDAQ:FGEN) Expected to Post Quarterly Sales of $27.56 Million

Brokerages expect that FibroGen, Inc. (NASDAQ:FGENGet Rating) will announce $27.56 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for FibroGen’s earnings. The lowest sales estimate is $13.40 million and the highest is $40.75 million. FibroGen posted sales of $38.43 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 28.3%. The business is scheduled to report its next earnings results after the market closes on Monday, January 1st.

On average, analysts expect that FibroGen will report full year sales of $131.45 million for the current fiscal year, with estimates ranging from $76.00 million to $168.68 million. For the next financial year, analysts forecast that the firm will report sales of $183.53 million, with estimates ranging from $120.00 million to $280.72 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow FibroGen.

FibroGen (NASDAQ:FGENGet Rating) last posted its earnings results on Monday, February 28th. The biopharmaceutical company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.77). The firm had revenue of $16.54 million during the quarter, compared to the consensus estimate of $47.65 million. FibroGen had a negative return on equity of 93.23% and a negative net margin of 123.25%. FibroGen’s revenue for the quarter was down 74.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.64) EPS.

FGEN has been the topic of several recent research reports. The Goldman Sachs Group cut their price objective on shares of FibroGen from $10.00 to $9.00 and set a “sell” rating on the stock in a research report on Tuesday, March 1st. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, StockNews.com began coverage on shares of FibroGen in a report on Thursday, March 31st. They set a “hold” rating on the stock. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.43.

FGEN stock opened at $8.41 on Friday. The firm has a 50-day moving average of $11.86 and a two-hundred day moving average of $13.05. The firm has a market capitalization of $782.15 million, a PE ratio of -2.68 and a beta of 0.91. FibroGen has a one year low of $8.31 and a one year high of $30.12.

A number of institutional investors have recently added to or reduced their stakes in FGEN. New York State Common Retirement Fund lifted its holdings in FibroGen by 6.1% in the first quarter. New York State Common Retirement Fund now owns 81,926 shares of the biopharmaceutical company’s stock valued at $985,000 after buying an additional 4,689 shares during the period. Institute for Wealth Management LLC. increased its holdings in FibroGen by 12.4% in the first quarter. Institute for Wealth Management LLC. now owns 22,207 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 2,445 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in FibroGen by 10.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 30,750 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 2,800 shares during the last quarter. Kestra Advisory Services LLC lifted its stake in FibroGen by 12.6% in the first quarter. Kestra Advisory Services LLC now owns 13,448 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 1,500 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in FibroGen by 237.3% during the first quarter. Assenagon Asset Management S.A. now owns 224,671 shares of the biopharmaceutical company’s stock worth $2,701,000 after buying an additional 158,058 shares during the last quarter. Institutional investors own 77.35% of the company’s stock.

About FibroGen (Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Recommended Stories

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.